2. Anti-infection Cell Cycle/DNA Damage Apoptosis
  3. Influenza Virus DNA/RNA Synthesis Apoptosis Parasite Bacterial Fungal
  4. Cynaroside

Cynaroside  (Synonyms: Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside)

Cat. No.: HY-N0540 Purity: 99.19%
COA Handling Instructions

Molarity Calculator

Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 32 nM. Cynaroside also is a promising inhibitor for H2O2-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities.

For research use only. We do not sell to patients.

Cynaroside Chemical Structure

Cynaroside Chemical Structure

CAS No. : 5373-11-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 99 In-stock
Solution
10 mM * 1 mL in DMSO USD 99 In-stock
Solid
5 mg USD 90 In-stock
10 mg USD 140 In-stock
25 mg USD 280 In-stock
50 mg USD 450 In-stock
100 mg USD 720 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Cynaroside:

Cynaroside Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 32 nM. Cynaroside also is a promising inhibitor for H2O2-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities[1][3][4][5].

IC50 & Target

IC50:32 nM (RNA polymerase inhibitor)[2]
In Vitro

Cynaroside promots macrophage phenotypic transition from pro-inflammatory M1 to anti-inflammatory M2, and mitigates sepsis-associated liver inflammatory damage.
? Cynaroside reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105 in vivo and in vitro.
? Cynaroside restores pyruvate kinase activity, inhibits glycolysis-related proteins including PFKFB3, HK2 and HIF-1α, and inhibits glycolysisrelated hyperacetylation of HMGB1 in septic liver.
? Cynaroside protects H9c2 cells against H2O2-induced apoptosis by decreasing ROS generation and inhibiting caspase activation in both the mitochondrial and death receptor pathways.
? Cynaroside maintains mitochondrial function by regulating Bcl-2 protein expression, as well as JNK and P53 expression[2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cynaroside Related Antibodies

Western Blot Analysis[2]

Cell Line: RAW264.7 cell
Concentration: 5µM, 10µM
Incubation Time: 2 h
Result: Reduced expression levels of IL-1β, IL-6 and TNF-α and HMGB1, suppressed M1 polarized phenotype in RAW264.7 cells.

Immunofluorescence[2]

Cell Line: RAW264.7 cell
Concentration:
Incubation Time: 4 h
Result: Decreased PKM2 nuclear translocation in hepatic macrophages of septic mice.

RT-PCR[2]

Cell Line: RAW264.7 cell
Concentration: 2.5µM, 5µM, 10µM
Incubation Time:
Result: Increased increased expression levels of M2 markers Arg-1, IL-10 andCD206.

Cell Viability Assay[3]

Cell Line: H9c2 cells
Concentration: 25, 50, 100 μg/mL
Incubation Time: 4 h
Result: Protected H9c2 cells from oxidative stress-induced cell injury.

Apoptosis Analysis[3]

Cell Line: H9c2 cells
Concentration: 25, 50, 100 μg/mL
Incubation Time: 4 h
Result: Decreased H2O2-induced apoptosis in H9C2 cells.
In Vivo

Cynaroside (i.p.; 5mg/kg) reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice model of sepsis[2]
Dosage: 5mg/kg
Administration: Cynaroside (i.p.; 5mg/kg)
Result: Inhibited PKM2 dimer formation in liver of septic mice.
Molecular Weight

448.38

Formula

C21H20O11
CAS No.
Appearance

Solid

Color

Light yellow to green yellow

SMILES

O=C(C=C(C1=CC(O)=C(O)C=C1)OC2=CC(O[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)C2=C4O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (185.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2303 mL 11.1513 mL 22.3025 mL
5 mM 0.4461 mL 2.2303 mL 4.4605 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 16.67 mg/mL (37.18 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.19%

COA (250 KB) HNMR (274 KB) LCMS (92 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2303 mL 11.1513 mL 22.3025 mL 55.7563 mL
5 mM 0.4461 mL 2.2303 mL 4.4605 mL 11.1513 mL
10 mM 0.2230 mL 1.1151 mL 2.2303 mL 5.5756 mL
15 mM 0.1487 mL 0.7434 mL 1.4868 mL 3.7171 mL
20 mM 0.1115 mL 0.5576 mL 1.1151 mL 2.7878 mL
25 mM 0.0892 mL 0.4461 mL 0.8921 mL 2.2303 mL
30 mM 0.0743 mL 0.3717 mL 0.7434 mL 1.8585 mL
40 mM 0.0558 mL 0.2788 mL 0.5576 mL 1.3939 mL
50 mM 0.0446 mL 0.2230 mL 0.4461 mL 1.1151 mL
60 mM 0.0372 mL 0.1859 mL 0.3717 mL 0.9293 mL
80 mM 0.0279 mL 0.1394 mL 0.2788 mL 0.6970 mL
100 mM 0.0223 mL 0.1115 mL 0.2230 mL 0.5576 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cynaroside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cynaroside5373-11-5Luteolin 7-glucoside Luteolin 7-O-β-D-glucosideInfluenza VirusDNA/RNA SynthesisApoptosisParasiteBacterialFungalPKM2RNA polymerase inhibitorantibacterialantifungalanticanceractivitiesantioxidantanti-inflammatoryapoptosiscardiovascularInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cynaroside
Cat. No.:
HY-N0540
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.